Drug Name | Drug Class | Formulation | FDA Approved/Clinical Trial Phase | Reference |
---|---|---|---|---|
Gold standard chemotherapeutic | ||||
Doxorubicin | Antibiotics/antineoplastics | 1995 | Bolis et al., 1978 | |
Carboplatin | Alkylating agents | 1989 | Adams et al., 1989 | |
Paclitaxel | Mitotic inhibitors | 1998 | Khanna et al., 2015 | |
Cyclophosphamide | Alkylating agents | 1959 | Handolias et al., 2016 | |
Gemcitabine | Antimetabolites | 2006 | Lorusso et al., 2006 | |
Melphalan | Alkylating agents | 2001 | Hasan and Jayson, 2003 | |
Cisplatin | Alkylating agents | 1978 | Monneret, 2011 | |
Topotecan | Miscellaneous antineoplastics | 1996 | Seiden et al., 2004 | |
Etoposide | Mitotic inhibitors | 1998 | Long et al., 2005 | |
Thiotepa | Alkylating agents | 2001 | Gordinier et al., 2002 | |
Targeted therapies | ||||
Bevacizumab | VEGF/VEGFR inhibitors | 2004 | Rossi et al., 2017 | |
Olaparib | PARP inhibitors | 2017 | Moore et al., 2018 | |
Niraparib | PARP inhibitors | 2017 | Essel and Moore, 2018 | |
Rucaparib | PARP inhibitors | 2018 | Dal Molin et al., 2018 | |
Current nanotechnology treatments and ongoing trials | ||||
Doxil | Antibiotics/antineoplastics | Pegylated liposomal doxorubicin | 1999 | Pisano et al., 2013 |
Lipodox | Antibiotics/antineoplastics | Pegylated liposomal doxorubicin | 2012 | Chou et al., 2006 |
Genexol-PM | Mitotic inhibitors | PEG-PLA polymeric micellar paclitaxel | Phase II | Lee et al., 2017 |
LEP-ETU | Mitotic inhibitors | Liposomal paclitaxel | Phase I | Damjanov et al., 2005 |
Paclical | Mitotic inhibitors | Paclitaxel micelles | Phase III | NCT00989131 |
OSI-211 | Antineoplastics | Liposomal lurtotecan | Phase II | Seiden et al., 2004 |
PARP, poly(adenosine diphosphate [ADP]-ribose) polymerase; PLA, polylactic acid; VEGF, vascular endothelial growth factor.